At Daiichi Sankyo Europe, our motto "Passion for Innovation. Compassion for Patients." goes far beyond medicine development. Our commitment to putting patients first shapes everything we do from our daily decisions to our long-term strategies.
By actively listening to the voices and experiences of patients and caregivers and actively collaborating with them, Daiichi Sankyo Europe is better equipped to focus on the outcomes that truly matter. This approach helps us enhance patient care, bridge the gap between medical innovation and patient-first solutions, and ultimately fulfil our global purpose: to enrich the quality of life for people around the world.
Global Heart Hub (GHH) is the first global non-profit organisation established to provide a voice for those living with or affected by cardiovascular disease1. As an alliance of heart patient organisations, aiming to create a unified global voice for those living with or affected by heart disease, GHH’s priorities closely align with Daiichi Sankyo’s aspiration to improve patient care through understanding patient needs. By working with GHH, Daiichi Sankyo gains valuable insights into the challenges faced by cardiovascular patients, enabling the development of initiatives that address these concerns effectively.
Since establishing our European SBU patient engagement function two years ago, our focus has been on working with patient organisations to understand and support their priorities. GHH was one of the early groups that the function became involved with and since then, DSE has been proud to be a member of their industry forum.
A key area of immediate connection with GHH has been women and cardiovascular disease (CVD). Daiichi Sankyo is committed to activities that advocate for a future where every woman has access to the care and support she deserves. Our partnership thus commenced when DSE was invited to support the Global Heart Hub International Roundtable Discussion on Late, Missed and Misdiagnosis of Heart Disease in Women which took place in Madrid, Spain in April 2024. The event convened 27 participants from 15 countries, including women with lived experiences, patient organisation leaders, public health experts, researchers, and clinicians. The roundtable identified four priority areas: healthcare system and medical education, research, patient & public engagement and awareness, policy change, and public health. These areas guide Global Heart Hub's efforts to enhance the screening, diagnosis, and treatment of cardiovascular disease in women.
More recently DSE was invited to support a GHH 1-year research project designed to explore women's experiences, awareness, and recognition of cardiovascular symptoms, investigating how these differ from traditionally recognised profiles, analysing how biases in healthcare impact women's experiences from symptom recognition to diagnosis and management.
Through these initiatives, DSE aims to support a deepened understanding and enhancement of the cardiovascular healthcare landscape for all.
As cardiovascular disease continues to be a leading cause of death in Europe2, it is imperative that all stakeholders unite to address this pressing challenge. The pharmaceutical industry has a responsibility to support patient organisations in full respect of compliance regulations, to help them develop their perspectives and advocate for those living with health conditions. Only by empowering patients to raise their voice can we achieve a true transformation of healthcare, prioritising the outcomes that matter to them.
If you are a patient and or patient organisation and want to know more about our commitment to patient care and medicines innovation, then please click here.
1 Global Heart Hub. About Us. Available at: https://globalhearthub.org/about/. Last accessed: July 2025.
2 Townsend N, Kazakiewicz D, Lucy Wright F, Timmis A, Huculeci R, Torbica A, Gale CP, Achenbach S, Weidinger F, Vardas P. Epidemiology of cardiovascular disease in Europe. Nat Rev Cardiol. 2022 Feb;19(2):133-143.
Enter your username and password here in order to log in on the website
Dear User,
if you want to login you accept our
cookie policy
.
LinkedIn
Mail 
